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800HIGHLIGHTS
 This study was designed to determine the effect of selective optogenetic simulation of vagal efferent activity on
left ventricular function in an animal (rat) model of MI-induced heart failure.
 Optogenetic stimulation of dorsal brainstem vagal pre-ganglionic neurons transduced to express light-sensitive
channels preserved LV function and exercise capacity in animals with MI.
 The data suggest that activation of vagal efferents is critically important to deliver the therapeutic benefit of








reLarge clinical trials designed to test the efficacy of vagus nerve stimulation (VNS) in patients with heart failure
did not demonstrate benefits with respect to the primary endpoints. The nonselective nature of VNS may
account for the failure to translate promising results of preclinical and earlier clinical studies. This study showed
that optogenetic stimulation of vagal pre-ganglionic neurons transduced to express light-sensitive channels
preserved left ventricular function and exercise capacity in a rat model of myocardial infarctioninduced heart
failure. These data suggested that stimulation of vagal efferent activity is critically important to deliver the
therapeutic benefit of VNS in heart failure. (J Am Coll Cardiol Basic Trans Science 2020;5:799–810)
©2020 TheAuthors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an
open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).C hronic heart failure is 1 of the most commoncauses of morbidity and mortality in thedeveloped world. Established pharmacolog-
ical treatment of heart failure that involves several
drug classes, including b-blockers and inhibitors of
renin-angiotensin-aldosterone system, improves
symptoms and reduces mortality. Yet, drug therapy
remains insufficient because cardiac function con-
tinues to deteriorate over time, and most patients
have poor prognosis (1).
Autonomic dysfunction characterized by sympa-
thetic activation and parasympathetic (vagal) with-
drawal accelerates the development and progression
of the disease (2–4). The current gold standard phar-
macological treatment includes drugs that limit the
sympathetic effects on the heart and kidneys (e.g., b-
blockers). However, stimulation of vagal efferent ac-
tivity to increase parasympathetic tone and redress
autonomic balance as a treatment for heart failure has
proved to be more difficult to achieve (5,6). Patients
with heart failure on optimal medical therapy with
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prognosis (7).
Electrical vagus nerve stimulation (VNS) has been
shown to reduce the extent of an acute myocardial
infarction (MI) (8–11) and slow the progression of
myocardial remodeling, as well as atrial and ven-
tricular dysfunction in animal models of chronic
heart failure (12–17). In the first human trial that
involved 32 patients with heart failure, De Ferrari
et al. (18) demonstrated that electrical stimulation of
the right vagus nerve using implanted devices
improved New York Heart Association functional
class, left ventricular (LV) function, and quality of
life. However, subsequent multicenter trials
designed to test VNS efficacy in large cohorts of
patients with heart failure reported mixed results.
Premchand et al. (19) showed improvements of the
ejection fraction and symptoms in another noncon-
trolled study that involved 60 patients (ANTHEM-HF
[Autonomic Neural Regulation Therapy to Enhance
Myocardial Function in Heart Failure] study),kłodowska-Curie Research Fellowship (Ref: 654691).
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801whereas Zannad et al. (20) and Gold et al. (21) re-
ported no effect of VNS on LV remodeling and
function or mortality in trials that involved 86
(NECTAR-HF [Neural Cardiac Therapy for
Heart Failure]) and 707 (INOVATE-HF [Increase of
Vagal Tone in Chronic Heart Failure]) patients.
However, there were reported improvements in
quality of life (20).
The mechanisms underlying the potential benefit
of VNS in heart failure remain poorly understood. The
cervical vagus is a mixed nerve containing sensory
and motor fibers at an approximate ratio of 4:1. The
nerve bundle contains branches that innervate most
of the viscera and sparse sympathetic fibers. There is
no experimental data to suggest that the VNS bene-
ficial effects on the failing heart observed in animal
and some human studies are due to the recruitment
of afferent (sensory) or efferent (motor) vagal fibers
(or both) by the electrical current pulses applied to
the nerve at the cervical level. Although attempts had
been made to design VNS devices for preferential
stimulation of vagal efferents (5,18), electrical prop-
erties of the nerve fibers that constitute the human
vagus nerve make selective fiber recruitment virtu-
ally impossible to achieve.
Further refinement of VNS as a potential treat-
ment for human heart failure may require develop-
ment of alternative methods of selective stimulation
of specific groups or subsets of vagal fibers. Selective
stimulation would be expected to maximize the ef-
ficacy and limit the side effects associated with the
recruitment of fibers that may not necessarily confer
any benefit on the failing heart (22). The optogenetic
approach involving transduction of mammalian
neurons to express the native or modified light-
sensitive channels from algae and activation of
these neurons using light provides the required level
of selectivity for experimental studies (23). Recently,
we and other laboratories used optogenetic tech-
niques to study the nervous mechanisms controlling
the heart (11,24,25). Our research group demon-
strated that stimulation of approximately 300 to 400
vagal pre-ganglionic neurons in the dorsal motor
nucleus of the vagus nerve (DVMN) markedly
reduced the extent of MI in an animal model (11).
These data provided direct evidence of effective
cardioprotection by selective stimulation of vagal
efferent activity. In the present study, we genetically
targeted the DVMN neurons to express the light-
sensitive channel ChiEF and determined the effect
of selective stimulation of the DVMN vagal efferent
projections using light (optoVNS) on LV function in a
rat model of MI-induced heart failure.METHODS
All the experiments were performed in accordance
with the European Commission Directive 2010/63/EU
(European Convention for the Protection of Verte-
brate Animals used for Experimental and Other Sci-
entific Purposes) and the United Kingdom Home
Office (Scientific Procedures) Act (1986) with project
approval from the University College London Insti-
tutional Animal Care and Use Committee. The rats
were group housed and maintained on a 12-h light
cycle (lights on 0700) and had ad libitum access to
water and food.
GENETIC TARGETING OF THE DVMN VAGAL
PRE-GANGLIONIC NEURONS. Vagal pre-ganglionic
neurons of the DVMN express transcriptional factor
Phox2 and were targeted to express a light-sensitive
chimeric channelrhodopsin derivative ChIEF fused
with a fluorescent protein tdTomato (ChIEF-
tdTomato) or enhanced green fluorescent protein
(eGFP) (control transgene) using lentiviral vectors
(LVV). Transgene expression was driven under the
control of a Phox2-activated promoter PRSx8 (26).
Validation of the specificity of vectors in transducing
the DVMN neurons was described in detail previously
(11,27). Pulses of blue (445 nm) light trigger precisely
timed depolarizations and action potential firing of
the DVMN neurons transduced to express ChIEF (11).
Male Sprague-Dawley rats (150 to 200 g; n ¼ 68)
were anesthetized with a combination of ketamine
(60 mg/kg intramuscularly) and medetomidine
(250 mg/kg intramuscularly). Adequate depth of sur-
gical anesthesia was maintained and confirmed by the
absence of a withdrawal response to a paw pinch.
With the head of the animal in a stereotaxic frame, a
midline dorsal neck incision was made to expose the
dorsal brainstem surface. Caudal populations of the
DVMN neurons were targeted bilaterally with 1
microinjection on each side that delivered viral par-
ticles of either LVV-PRSx8-eGFP or LVV-PRSx8-
ChIEFtdTomato (Figure 1A). The microinjections
(0.5 ml at a rate of 0.1 ml/min) were made at 0.5 mm
rostral, 0.6 mm lateral, and 0.8 mm ventral from the
calamus scriptorius. After the microinjections, the
wound was sutured, and anesthesia was reversed
with atipamezole (1mg/kg; intramuscularly). Post-
operatively, the animals received buprenorphine
(0.05mg/kg/day, subcutaneously) analgesia for
3 days. No complications were observed after the
surgery, and the animals gained weight normally.
OPTRODE IMPLANTATION. Two weeks after the mi-
croinjections of viral vectors, the animals were
FIGURE 1 Design of the Study and Genetic Targeting of Vagal Pre-Ganglionic Neurons to Express Light-Sensitive Channel ChIEF for Selective Stimulation of Vagal
Efferent Activity Using Light
(A) The experimental timeline, study protocols, and schematic drawings of the key methods. The rat brain is drawn in sagittal and coronal projections to illustrate the
anatomical position of the dorsal motor nucleus of the vagus nerve (DVMN) targeted with a lentiviral vector (LVV) to express ChIEFtdTomato under the control of the
PRSx8 promoter. The caudal aspect of the rat brain is also drawn in the sagittal projection to illustrate the approximate positioning of the optrode implant to stimulate
the cell bodies of DVMN vagal pre-ganglionic neurons using light. (B) A photomicrograph of a representative coronal section of the rat dorsal brainstem taken at low
magnification illustrating a representative example of ChIEFtdTomato expression in the caudal region of the DVMN. Arrows point at ventrally projecting axons of the
transduced DVMN neurons, forming the efferent vagus nerve. (C) A high magnification image illustrating ChIEFtdTomato expression by vagal preganglionic neurons of
the DVMN. White arrows point at neuronal cell bodies; open arrows point at severed neuronal axons displaying specific membrane localization of ChIEFtdTomato. (D)
Representative raw data illustrating the effect of light stimulation (445 nm, 10 ms pulse, 15 Hz) of DVMN neurons expressing ChIEFtdTomato on heart rate (HR),
arterial blood pressure (ABP), and the efferent activity of the cervical vagus nerve in a urethane-anesthetized rat. (E) Evoked efferent vagus nerve action potential
firing induced by 10 ms pulse of light delivered at 1 Hz to stimulate the DVMN vagal preganglionic neurons expressing ChIEFtdTomato. bpm ¼ beats/min; CC ¼ central
canal; LAD ¼ left anterior descending coronary artery; MI ¼ myocardial infarction.
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802anesthetized with ketamine (60 mg/kg intramuscu-
larly) and medetomidine (250 mg/kg intramuscularly),
and an optrode (Art Photonics, Berlin, Germany) was
implanted to reach the dorsal surface of thebrainstem for optimal light delivery to the groups of
transduced vagal neurons. Two screws were placed
into the skull, and the implant was secured in place
with dental acrylic (Figure 1A). Anesthesia was
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803reversed with atipamezole (1 mg/kg intramuscularly).
Carprofen (5 mg/kg/day subcutaneously) was given
for post-operative analgesia for 3 days, and the ani-
mals were allowed to recover for 7 days. Rats were
300 to 350 g at the time of the main experiment.
RECORDING THE EFFERENT ACTIVITY OF THE
VAGUS NERVE. Rats (n ¼ 4) transduced to express
ChiEFtdTomato by the DVMN neurons were anes-
thetized with urethane (induction: 1.3 g/kg, intraper-
itoneally; maintenance: 10 to 25 mg/kg/h
intravenously) and instrumented as described in
detail previously (28,29). Adequate anesthesia was
ensured by maintaining stable levels of arterial blood
pressure (ABP) and heart rate and showing lack of
responses to a paw pinch. The femoral artery and vein
were cannulated for measurements of blood pressure
and administration of anesthetic, respectively. The
trachea was cannulated, and the animal was me-
chanically ventilated with air supplemented with
oxygen using a positive pressure ventilator with a
tidal volume of approximately 1ml/100 g of body
weight and ventilator frequency similar to the resting
respiratory rate (w60 strokes/min). Partial pressure of
oxygen, partial pressure of carbon dioxide, and pH of
arterial blood were measured regularly and kept
within physiological ranges (partial pressure of oxy-
gen: 95 to 105mm Hg; partial pressure of carbon di-
oxide: 35 to 45mm Hg, and pH 7.35 to 7.45) by
adjusting the tidal volume and/or ventilator fre-
quency as well as the level of supplemental oxygen.
Body temperature was maintained at 37.00.5C.
The right vagus nerve was dissected, isolated from
the surrounding tissues, placed on silver wire
recording electrodes, and covered with dental
impression material. The recorded signal was ampli-
fied (10,000), filtered (80 to 1,500 Hz), and sampled
at a rate of 5 kHz using a Power1401 interface and
Spike2 software (Cambridge Electronic Design,
Cambridge, United Kingdom).
MODEL OF MI-INDUCED HEART FAILURE. MI leading
to progressive impairment of LV function in rats was
induced using a left anterior descending coronary
artery (LAD) occlusion technique described in detail
in the published reports (30). One week following
optrode implantation (Figure 1A), the rats were
anesthetized with ketamine (60 mg/kg intramuscu-
larly) and medetomidine (250 mg/kg intramuscu-
larly), and artificially ventilated following
endotracheal intubation. A left thoracotomy was
performed to expose the heart, the pericardium
was opened, the heart was exteriorized, and the LAD
was ligated just below the left atrial appendageusing 4-0 braided silk suture. Successful coronary
occlusion was confirmed by pallor of the anterior LV
wall. Sham ligations involved the same sequence of
procedures, including placement of the suture
through the ventricular wall but without the occlu-
sive tying. The chest incision was closed, the lungs
were re-inflated, and artificial ventilation was dis-
continued once the animal started to breathe spon-
taneously. Anesthesia was reversed with
atipamezole (1 mg/kg intramuscularly). Carprofen
(5 mg/kg/day subcutaneously for 3 days) was given
for post-operative analgesia. Post-operative mortal-
ity within the first 48 h after MI was 26%. All ani-
mals that survived beyond 48 h post-MI also
survived the remainder of the study period.
EXPERIMENTAL GROUPS. On the basis that the
minimum physiologically relevant effect of efferent
vagus stimulation would be to prevent reduction in
the ejection fraction after LAD occlusion by 8%, we
estimated that at least 8 animals in each of the 4
experimental groups would be required (a ¼ 0.01;
1-b ¼ 0.9). The rats were randomized into 4 experi-
mental groups (the rationale for the number of
animals included in each of the groups at the begin-
ning of the study is given in the following): 1) sham/
shamVNS (n ¼ 8): sham-operated animals expressing
eGFP in the DVMN; 2) sham/optoVNS (n ¼ 10): sham-
operated animals expressing ChiEFtdTomato in the
DVMN; 3) post-MI/shamVNS (n ¼ 13): animals with
LAD occlusion expressing eGFP in the DVMN; and 4)
post-MI/optoVNS (n ¼ 19): animals with LAD occlu-
sion expressing ChiEFtdTomato in the DVMN
(Figure 1A). Ten animals were included in sham/
optoVNS group to allow for 20% dropout rate due to a
potential lack of (or weak) ChiEFtdTomato expression
in the DVMN due to variations of titer between
different preparations of the vector. Thirteen animals
were included in post-MI/shamVNS group to allow for
an approximate 40% dropout of subjects that devel-
oped small infarcts (<30%). Nineteen rats were
included in post-MI/optoVNS to allow for a potential
20% dropout rate due to lack of ChiEFtdTomato
expression and/or 40% dropout due to the develop-
ment of small infarcts.
The dorsal brainstem was illuminated in all the
animals via the implanted optrode with 445-nm light
pulses (10 ms, 15 Hz) for 15 min every 48 h for
4 weeks, which commenced 48 h after the LAD oc-
clusion or sham surgery (Figure 1A). To minimize the
stress of the animals, light stimulation was performed
under mild sedation (1% isoflurane in 1:1 oxygen/air
mixture).
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804EVALUATION OF EXERCISE CAPACITY. The exercise
capacity of experimental rats was assessed using a
single lane treadmill (Panlab Harvard Apparatus,
Barcelona, Spain) as previously described (24,31). To
determine the exercise capacity, treadmill speed was
raised in increments of 5 cm/s every 5 min after an
initial 15 min at 20 cm/s until the animal was unable
to maintain pace with the moving belt and entered
the stationary platform at the end of the treadmill 4
times within a 2-min period, which was the humanely
defined point of exhaustion. The distance covered by
the animal was recorded, and exercise capacity
expressed as work done in Joules.
ECHOCARDIOGRAPHY. The animals were anes-
thetized with isoflurane (induction 4%, maintenance
2% in 1:1 oxygen/air mixture). Echocardiographic
assessment of LV function was performed using a
Vevo 2100 high-resolution ultrasound system with a
MS250 13-24MHz linear array transducer (Visual-
Sonics, Toronto, Ontario, Canada), with simultaneous
heart rate monitoring (lead II electrocardiography). In
a B-mode acquisition, the ejection fraction was
determined using a parasternal long-axis view of the
LV, measuring the length of the ventricle at the end of
systole and diastole. Three perpendicular short-axis
images were acquired equidistantly along the length
of the LV to segment the endocardial border. The LV
volumes were approximated using Simpson’s rule
(32). Using an apical 4-chamber view in Doppler
mode, blood flow velocity across the mitral valve was
also measured. The ratio of flow velocities during the
early and atrial ventricular filling phases (E/A ratio)
was calculated to assess diastolic function (33).
HEMODYNAMIC STUDIES. After the echocardio-
graphic study, all animals underwent invasive he-
modynamic assessment under urethane (1.3 g/kg
intraperitoneally) anesthesia. Adequate depth of
anesthesia was ensured by stable levels of ABP and
heart rate in addition to the absence of a withdrawal
response to a paw pinch. The femoral artery was
cannulated for the purpose of measuring ABP. The
trachea was cannulated, and the animal was artifi-
cially ventilated with room air using a positive pres-
sure ventilator (Harvard Apparatus, Holliston,
Massachusetts) with a tidal volume of approximately
2.5 ml and a frequency similar to the spontaneous
breathing rate (w60 strokes/min). Body temperature
was maintained at 37.0  0.5C. A 2-F Millar pressure
catheter (model SPR-407; Millar Instruments, Hous-
ton, Texas) was advanced via the right carotid artery
into the LV chamber to record LV pressure (LVP).Following 30 min of stabilization, LVP, ABP, and
standard lead II electrocardiogram were recorded for
15 min using a Power1401 interface and Spike2 soft-
ware (Cambridge Electronic Design, Cambridge,
United Kingdom). The ABP averaged waveforms were
used to calculate the mean arterial pressure. The LVP
average waveforms were used to calculate LV end-
systolic pressure (LVESP) and LV end-diastolic pres-
sure (LVEDP). The first differential of LVP, LV dP/dt
was calculated to determine its maximum, LV dP/
dtMAX. At the end of the hemodynamic studies, the
heart was arrested with potassium chloride and
removed for the assessment of infarct size.
ASSESSMENT OF INFARCT SIZE. The extent of MI
was determined as described in detail previously
(30,34,35). Briefly, the LV was cut into 5 to 6 trans-
verse slices of approximately 1.5 mm thickness. The
images of the slices were taken, and the length of the
entire endocardial and epicardial circumferences, as
well as the length of the scar muscle for endocardial
and epicardial surfaces, were determined by
computerized planimetry using ImageJ software
(National Institutes of Health, Bethesda, Maryland).
The ratio of the length of the scar and the entire
surface circumferences defined the infarct size for
endocardial and epicardial surfaces. Infarct size
(percentage) was calculated as an average of the
infarcted endocardial and epicardial surfaces. The
extent of myocardial necrosis of these well-healed
infarcts was determined from the circumference
rather than from the volume of the infarct because
the latter underestimates the initial loss of the
myocardium (30).
HISTOLOGY. At the end of the hemodynamic study,
the brains were removed and fixed in 4% phosphate-
buffered (0.1 M, pH 7.4) paraformaldehyde solution.
After cryoprotection (30% sucrose), the brainstem
was isolated, and a sequence of transverse slices
(30 mm) was cut to determine the extent of ChiEF-
tdTomato or eGFP expression by the DVMN neurons.
DATA ANALYSIS. Recordings of the vagus nerve ac-
tivity and cardiovascular variables were analyzed
using Spike2 software. Differences between the
experimental groups were assessed using GraphPad
Prism 6 software (GraphPad, San Diego, California).
Comparisons were made using 2-way analysis of
variance followed by Sidak’s p value correction for
multiple comparisons or Student’s t-test, as appro-
priate. Data were reported as individual values and
mean  SEM. Differences with p < 0.05 were
considered significant.
FIGURE 2 Optogenetic Stimulation of Vagal Efferent Activity Improves Exercise
Capacity and Ejection Fraction in MI-Induced Heart Failure in Rats
(A) Representative sections of the left ventricle (LV) from a sham-operated animal
(sham/sham vagus nerve stimulation [VNS] group), an animal with MI expressing
enhanced green fluorescent protein (eGFP) in the DVMN after 4 weeks of sham-
stimulation (post-MI/shamVNS group), and an animal with MI expressing ChiEF-
tdTomato in the DVMN after 4 weeks of efferent vagus stimulation using light (post-
MI/optoVNS group). Summary data illustrate infarct sizes determined by computerized
planimetry of LV sections of rats transduced to express eGFP or ChiEFtdTomato by the
DVMN neurons after 4 weeks of light stimulation commencing 2 days after the occlusion
of the left anterior descending artery (Student’s t-test). (B and C) Summary data
illustrating the exercise capacity and LV ejection fraction of rats transduced to express
eGFP or ChiEFtdTomato by the DVMN neurons after 4 weeks of light stimulation
commencing 2 days after the occlusion of the left anterior descending artery or sham
surgery. Data are presented as individual values and mean  SEM. Comparisons are
made using 2-way analysis of variance followed by Sidak’s correction for multiple
comparisons. Abbreviations as in Figure 1.
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805RESULTS
Expression of ChIEFtdTomato by the vagal pre-
ganglionic neurons residing in the caudal regions of
the left and right DVMN was confirmed in all the
animals that received bilateral microinjections of
LVV-PRSx8-ChIEFtdTomato (Figures 1B and 1C).
Strong tdTomato fluorescence was observed in the
ventral projections of the transduced DVMN neu-
rons, forming the efferent vagus nerve (Figure 1B).
Pulses of 445 nm light (10 ms) applied to the dorsal
brainstem of rats transduced to express ChIEF-
tdTomato by the DVMN vagal pre-ganglionic neu-
rons triggered a volley of action potentials in the
cervical vagus with a mean delay of 27  2 ms
(n ¼ 4) (Figures 1D and 1E). Calculated conduction
velocity of 0.8 m/s was consistent with the prop-
erties of the rat DVMN cardiac vagal pre-ganglionic
neurons that have C-fiber axons (36). Stimulation of
DVMN neurons expressing ChIEF with 10-ms pulses
applied at a frequency of 15 Hz led to a robust
increase in vagal efferent activity and was associ-
ated with a reduction in heart rate (by 30  12
beats/min; 8.5% reduction; p ¼ 0.037) and mean
ABP (by 15  4 mm Hg) during the period of
stimulation (Figure 1D).
The average infarct size in the post-MI/shamVNS
group was 33.4  1.6 (n ¼ 13); in the post-MI/
optoVNS group it was 29.9  1.3 (n ¼ 19; p ¼ 0.09).
Four animals in the post-MI/shamVNS group and 7
animals in the post-MI/optoVNS experimental group
developed small infarcts (<30%). In accord with the
study design, the data obtained in 9 animals in the
post-MI/shamVNS group and 12 animals in the post-
MI/optoVNS group that developed infarcts $30%
were included in the analysis. There was no differ-
ence in mean infarct size between the 2 groups
(p ¼ 0.14) (Figure 2A).
Exercise capacity was significantly lower in post-
MI rats expressing eGFP in the DVMN compared
with sham-operated animals (0.28  0.03 kJ in post-
MI/shamVNS group vs. 0.56  0.08 kJ in sham/
shamVNS group; p ¼ 0.039) (Figure 2B). Optogenetic
stimulation of the DVMN neurons expressing
ChIEFtdTomato enhanced the exercise capacity in
sham-operated animals (1.05  0.12 kJ in sham-
operated rats expressing ChiEFtdTomato vs. 0.56 
0.08 kJ in sham-operated rats expressing eGFP;
p < 0.001) (Figure 2B) and improved the
exercise capacity in animals with LAD occlusion










Body weight (g) 431  18 406  29 453  18 391  5
Infarct size — — 34.9  0.7 33.2  0.8
HR (beats/min, under isoflurane) 348  9 380  12 364  12 389  12
Ejection fraction (%) 49.6  5.1 76.3  2.3 32.7  3.0 49.3  3.3
E/A ratio 1.2  0.1 1.6  0.1 0.9  0.1 1.2  0.1
HR (beats/min, under urethane) 371  15 380  19 363  19 380  13
dP/dtmin (mm Hg/s) 6,136  269 6,774  391 4,348  275 5,550  176
Pulse pressure (mm Hg) 52  4 51  2 36  4 51  5
LV to body weight ratio 2.12  0.07 1.92  0.06 2.19  0.08 2.24  0.05
RV to body weight ratio 0.38  0.01 0.37  0.01 0.42  0.02 0.36  0.02
Lung fluid (%) 77.5  0.3 77.8  0.5 77.3  0.3 78.4  0.3
Values are mean  SEM.
dP/dtmin ¼ maximum rate of left ventricular pressure decrease; HR ¼ heart rate; LV ¼ left ventricle;
MI ¼ myocardial infarction; RV ¼ right ventricle; VNS ¼ vagus nerve stimulation.
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806(0.56  0.04 kJ in post-MI rats expressing ChiEF-
tdTomato vs. 0.28  0.03 kJ in post-MI rats
expressing eGFP; p ¼ 0.021) (Figure 2B).
Development of MI-induced heart failure in
this model was evident from a significant
reduction of ejection fraction (32.7  3.0% in the
post-MI/shamVNS group vs. 49.6  5.1% in the sham/
shamVNS group; p ¼ 0.011) (Figure 2C), which indi-
cated systolic dysfunction. Optogenetic stimulation
of vagal pre-ganglionic neurons prevented MI-
induced reduction in the ejection fraction (49.3 
3.3% in post-MI rats expressing ChiEFtdTomato vs.
32.7  3.0% in post-MI rats expressing eGFP;
p ¼ 0.005). Significant increases in contractility were
observed in sham-operated animals. Optogenetic
stimulation of the DVMN increased the ejection frac-
tion by 26% (76.3  2.3% in sham-operated rats
expressing ChiEFtdTomato vs. 49.6  5.1% in sham-
operated rats expressing eGFP; p < 0.001). There
were no differences in E/A ratio and heart rate
(measured under isoflurane anesthesia) between the
experimental groups (Table 1).
Matching improvements in LV function as a result
of optogenetic stimulation of the DVMN neuronal
activity were recorded during invasive assessment of
cardiac function under terminal urethane anesthesia
(Figure 3, Table 1). Optogenetic stimulation of the
DVMN prevented MI-induced reduction in LV dP/
dTmax (7,673  332 mm Hg/s in post-MI rats express-
ing ChiEFtdTomato vs. 5,656  495 mmHg/s in post-
MI rats expressing eGFP; p < 0.001), in LVESP (122 
4 mm Hg in post-MI rats expressing ChiEFtdTomato
vs. 106  3 mm Hg in post-MI rats expressing eGFP;p ¼ 0.019), and in mean arterial pressure (78 
3 mm Hg in post-MI rats expressing ChiEFtdTomato
vs. 66  3 mm Hg in post-MI rats expressing eGFP;
p ¼ 0.043) (Figure 3). An increase in LVEDP associated
with the development of LV dysfunction was reduced
by vagal efferent stimulation (5.0  0.7 mm Hg in
post-MI rats expressing ChiEFtdTomato vs. 7.5 
0.6 mm Hg in post-MI rats expressing eGFP;
p ¼ 0.024) (Figure 3). Significant increases in LV dP/
dTmax and LVESP as a result of optogenetic stimula-
tion of the DVMN neurons were also observed in
sham-operated animals (Figure 3). There were no
differences in heart rate (measured under urethane
anesthesia) between the experimental groups
(Table 1).
DISCUSSION
The data obtained in the present study showed that
optogenetic stimulation of vagal pre-ganglionic neu-
rons of the DVMN (optoVNS) for 15 min every 48 h
over 4 weeks following LAD occlusion preserved LV
systolic function and maintained exercise capacity in
a rat model of heart failure. These data are consistent
with the results of earlier studies that showed that
optogenetic stimulation of the DVMN neuronal ac-
tivity protects the heart against acute ischemia/
reperfusion injury in a rat model of MI (11), and also
increases LV contractile responses to b-adrenoceptor
stimulation and improves exercise capacity in healthy
rats (24). Together, these data suggested that stimu-
lation of vagal efferent activity originating from the
DVMN might be critically important to confer the
therapeutic benefit of VNS in heart failure.
Cardiac vagal efferent activity originates from
populations of vagal pre-ganglionic neurons residing
in 2 brainstem nuclei: the DVMN and the nucleus
ambiguus (37,38). Control of pacemaker tissue, and
thus, heart rate is provided predominantly by neu-
rons of the nucleus ambiguus. Although most of the
DVMN neurons innervate the visceral organs, a sub-
population of these cells with cardiac projections
provides functional innervation of the LV and mod-
ulates its electrical (39) and contractile properties
(27). Activity of DVMN neurons has a relatively small
effect on heart rate (37).
The intermittent stimulation of the DVMN (which
lacks major chronotropic effects) preserved cardiac
function in rats with MI (as shown in this study),
which was consistent with the results of some previ-
ous reports that suggested that the beneficial effects
of VNS in heart failure were not entirely dependent
on lowering heart rate (13–15). This was an important
FIGURE 3 Optogenetic Stimulation of Vagal Efferent Activity Preserves LV Function in MI -Induced Heart Failure in Rats
Summary data illustrating the values of (A) the maximum first differential of LV pressure (LV dP/dtmax), (B) LV end-systolic pressure (LVESP), (C) mean arterial blood
pressure (MAP), and (D) LV end-diastolic pressure (LVEDP) in rats transduced to express eGFP or ChiEFtdTomato by the DVMN neurons after 4 weeks of light
stimulation commencing 2 days after the occlusion of the left anterior descending artery or sham surgery. Data are presented as individual values and mean  SEM.
Comparisons are made using 2-way analysis of variance followed by Sidak’s correction for multiple comparisons. Abbreviations as in Figures 1 and 2.
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807conclusion to draw in the context of a strong clinical
association between low chronotropic vagal tone and
the risk of death after MI or in established heart
failure (40,41), and of the effectiveness of pharma-
cological interventions that lower heart rate (e.g.,
b-blockers and If inhibitors) (42–44). In most clinical
trials of VNS in heart failure, the stimulating elec-
trodes were placed on the right cervical vagus nerve,
with the aim of lowering the heart rate, but it was not
reliably attained (20).
Several mechanisms that might underlie the
beneficial effects of VNS on the failing heart were
proposed, including improvements of autonomic
balance via sympathetic inhibition, inhibition of
renin-angiotensin system activity, and anti-
inflammatory effects of vagus stimulation (5,45). Se-
lective efferent VNS applied in this study was likely to
activate some or all of these mechanisms, whereas
the observed effects of optogenetic stimulation of theDVMN on myocardial function in sham-operated an-
imals suggested a plausible additional and/or alter-
native mechanism. Surprisingly, the effect of long-
term VNS on a healthy heart has never been
described, because the design of all of the preceding
studies that investigated the effect of VNS in heart
failure (12–15,17) excluded the experimental group(s)
of healthy subjects (“sham heart failure” groups)
receiving the stimulation. In this study, we observed
proportionally similar improvements in key measures
of LV systolic function and exercise capacity in
groups of rats with permanent LAD occlusion and in
sham-operated animals. These data were consistent
with the previously reported results that showed that
optogenetic stimulation of DVMN neuronal pro-
jections enhanced myocardial contractility and
responsiveness of the ventricular myocardium to
b-adrenoceptor stimulation (24). These effects of
DVMN stimulation were associated with reduced
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808myocardial expression of G-proteincoupled receptor
kinase 2 (GRK2) and b-arrestin 2 (24). GRKs phos-
phorylate b-adrenoceptors and recruit arrestins to
block receptor coupling to G-proteins, which leads to
receptor desensitization and internalization (46).
Increased expression and activity of GRKs contribute
to the progressive decline of myocardial contractile
function in heart failure (47). Therefore, inhibition of
GRKs was proposed as a potential therapeutic strat-
egy of heart failure treatment (47). We recently pro-
posed (38) that GRK2 and arrestin expression in
ventricular cardiomyocytes is under parasympathetic
control, with vagal withdrawal (e.g., in heart failure)
leading to upregulation and enhanced vagal activity
(e.g., in exercise training) leading to down-regulation
of expression, with apposite changes in contractility.
Cardiac projections of a subset of the DVMN neu-
rons innervate the LV and modulate its electrical (39)
and contractile properties (27). It is plausible that
optogenetic stimulation of the DVMN activates the
neuronal pathways and ventricular molecular mech-
anisms similar to that recruited by cardiac contrac-
tility modulation, which is a novel therapeutic
approach of heart failure treatment that involves
application of an electrical current during the ven-
tricular absolute refractory period (48,49). The high
voltage (w7.5V) applied in cardiac contractility mod-
ulation would be sufficient to capture the autonomic
nerves, including parasympathetic fibers innervating
the ventricular myocardium (50).
If this hypothesis is correct, then the VNS-based
heart failure therapy should aim at stimulating the
activity of vagal efferent fibers innervating the ven-
tricles. VNS devices used in clinical trials conducted
to date were not developed with an attempt to recruit
specific vagal projections. Electrical stimulation
applied to the cervical vagus preferentially activates
sensory fibers because they have a lower activation
threshold than efferent fibers (51). Experiments in
large animals (pigs and dogs) demonstrated that low
current stimulation (up to w2 mA) recruits afferent
fibers predominantly and activates autonomic reflex
pathways, which lead to increases in heart rate due to
inhibition of vagal activity centrally (52,53). Applica-
tion of higher VNS currents (>2.5 mA) is required for
stimulation of efferent fibers to achieve vagally
mediated lowering of the heart rate (53). No changes
in heart rate in response to electrical VNS are
observed when the effects of afferent and efferent
fiber stimulation are in balance. These studies led to
the development of a concept of a “neural fulcrum,”which was defined as the operating point based on
the frequency–amplitude-pulse width of VNS, in
which the stimulation has no effect on heart rate (51).
The efficacy of VNS applied within the neural fulcrum
is currently being tested in the ongoing ANTHEM-
HFrEF trial (54). Because recruitment of efferent fi-
bers requires more aggressive stimulation, simulta-
neous capture of vagal afferents may lead to
significant side effects, including dysphonia, neck
pain, and cough, as reported by the investigators of
the NECTAR-HF trial, in which no beneficial effect of
VNS on LV function was observed (20).
CONCLUSIONS
The data obtained in this study suggest that stimu-
lation of vagal efferent innervation of the ventricles
might be critically important to deliver the thera-
peutic benefit of VNS in chronic heart failure.
A revised approach to the electrical VNS may be
necessary to minimize the side effects that currently
restrain the intensity of stimulation required for the
effective recruitment of cardiac vagal efferent activ-
ity. The data reported here might be important for
further development of the electrical VNS technology
for targeted stimulation of a select group or subset of
fibers within the trunk of the vagus nerve. This would
also require detailed functional anatomical mapping
of the fascicular organization of the human cervical
vagus (22); this work is ongoing. Although opto-
genetic techniques are currently limited to preclinical
research, advances in human gene therapy point the
way toward eventual clinical applications of the
technology. VNS using light (optoVNS) can be applied
at the cervical level, and thus, can circumnavigate
limitations posed by the complex anatomy of the
vagus nerve and nonspecific nature of the whole
nerve electrical stimulation.
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PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: VNS has
been shown to slow the progression of myocardial
remodeling and dysfunction in animal models of chronic
heart failure. However, several multicenter clinical trials
designed to test the efficacy of VNS in large cohorts of
patients with heart failure did not demonstrate similar
benefits with respect to the primary clinical endpoints.
The nonselective nature of VNS, delivered by implantable
stimulators placed on the nerve at the cervical level, may
account for the failure to translate promising results of
preclinical studies. To maximize the efficacy and limit the
side effects, further development of VNS as a potential
treatment for heart failure may require methods that
allow selective stimulation of specific groups or subsets
of vagal fibers.
TRANSLATIONAL OUTLOOK: Stimulation of vagal
efferent projections to the ventricle may be critically
important to deliver the therapeutic benefit of VNS in
heart failure. A refined approach to VNS may be necessary
to minimize the side effects that currently restrain the
intensity of stimulation, which is required for the
recruitment of cardiac vagal efferent innervation.
Although optogenetic techniques are currently limited to
research in animals, advances in human gene therapy
point the way toward eventual clinical applications of the
technology. VNS using light (optoVNS) can be delivered
at the cervical level, and therefore, can circumnavigate
limitations posed by the complex anatomy of the cervical
vagus nerve and the nonspecific nature of the whole
nerve electrical stimulation.
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